期刊文献+

缺血性脑损伤后血管生成素表达及作用机制的研究进展

下载PDF
导出
出处 《中国康复医学杂志》 CAS CSCD 2004年第7期549-551,共3页 Chinese Journal of Rehabilitation Medicine
基金 国家自然科学基金项目(No.30271671)
  • 相关文献

参考文献28

  • 1Davis S,Aldrich TH,Jones PF,et al. Isolation of angiopoietin-1, a ligancd for the TIE2 receptor, by secretionx trap expression cloning[J].Cell, 1996, 27(87):1161-1169.
  • 2Maisonpierre PC, Suri C,Jones PF,et al. Angiopoietin-2,a natural antagonistor for Tie2 that distrupts in vivo angiogenesis[J].Science, 1997,277(4):55-60.
  • 3Valenzuela DM, Griffiths JA,Rojas J,et al. Angiopoietins 3 and 4:Diverging gene counter part sin mice and humans[J].Proc Natl Acad Sci USA, 1999,96(5):1904-1909.
  • 4Andreas P, David F,Keyvan M,et al. Angiopoietin-1 inhibits endothelial cell apoptosis via Akt/Survivin pathway [J].Biol Chem,2000,275 (13): 9102-9105.
  • 5Kim I,Kim HG,Moon SK,et al.Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin seeretion[J].Cire Res,2000,86 (9):952-956.
  • 6Maisonpierre PC,Berhard W,Pamela J,et al. Chemotaetic properties of angiopoietin-1 and angiopoietin-2,1igands for the endothelial specific receptor tryosine kinase tie2 [J]. Bio Chem,1998,273(29):18514- 18521.
  • 7Sato TN, Tozawa Y,Deutseh U,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation[J]. Nature,1995,376 (6535): 70-74.
  • 8Huang YQ,Li JJ,Karpatkin S. Identification of a family of alternatively spliced mRNA specie of angiopoietin-1 [J]. Blood,2000,95 (6): 1993-1999.
  • 9Mezquita J, Mezquita B, Pau M, et al. Characterization of a novel form of angiopoietin-2 (Ang-2B) and expression of VEGF and angiopoietin-2 during chicken testicular development and regression[J]. Biochem and Biophys Res Commu,1999,260(2): 492-498.
  • 10Kim I,Kim JH,Ryu YS,et al. Characterization and expression of a novel alternatively spliced human angiopoietin-2[J]. Biol Chem, 2000,275(24):18550- 18556.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部